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Allogeneic stem cell transplantation (ASCT) is a complex medical procedure for some patients with hemato-
logic malignancies. Most ASCTs occur at academic centers where either medical residents (house staff [HS]) or
advanced practice providers (APPs) provide daily care. As a result of increasing work-hour regulations, APPs
have assumed greater responsibilities, including those traditionally held by HS. In this study we evaluate ASCT
patient outcomes by inpatient provider service. A retrospective, single-center chart review of ASCT patients
was performed. ASCT patients admitted to an HS service fromMay 2011 to May 2012 (N ¼ 86) were compared
with ASCT patients admitted to a newly formed APP service from October 2012 to October 2013 (N ¼ 81). As
part of a secondary sensitivity analysis, we compared ASCT patients on the APP service to a subset of ASCT
patients admitted to the HS service also from October 2012 to October 2013 (n ¼ 27). Our primary outcomes
were 100-day survival and relapse-free survival rates. Additional outcomes included length of stay (LOS),
inpatient complications, and ordering behavior. Our primary pre- and post-analyses found no differences in
100-day overall survival and 100-day relapse-free survival rate between the services. The rate of pneumonia
was lower on the APP service (15% versus 28%, P ¼ .04), with no signiﬁcant differences in other infectious
complications. HS ordered more blood cultures (6.7 versus 4.2, P ¼ .03) per patient than the APP service. There
was no difference in LOS, readmission rates, or inpatient mortality. With regards to our secondary sensitivity
analysis, no differences were found in 100-day overall survival and 100-day relapse-free survival rates
between the services. There was a decreased LOS on the APP service (29.4 versus 37.2 days, P¼ .01). HS ordered
more blood cultures (9.3 versus 4.2, P < .01) and more radiological ﬁlms (8.1 versus 5.2, P ¼ .05) per patient
than the APP service. This increased ordering and LOS was associated with an increase in mean hospital
charges on the HS service (P ¼ .04). ASCT patients on an APP service had similar 100-day outcomes as those on
the HS service. In the setting of limited resources, APPs are potential alternative providers for complex
transplant inpatients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stem cell transplantation (ASCT) is a poten-
tially curative, high-risk procedure for the treatment of select
patients with hematologic malignancies [1-3]. The care of
these patients most often occurs at tertiary academic referraledgments on page 1697.
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ty for Blood and Marrow Transplantation.centers where medical residents (house staff [HS]) or nurse
practitioners and physician assistants (advanced practice
providers [APPs]) provide the day-to-day care under the
supervision of an attending physician [4]. Over the last 2
decades there has been an increase in both the number and
complexity of ASCTs performed each year. From 1994 to 2005
the overall number of ASCTs increased by 45%, with an
increased proportion of higher risk transplants using unre-
lated donors and cord blood [5].
Simultaneously, along with the increased number and
complexity of ASCTs there has been a change in medical
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the roles of clinicians providing the daily care for these pa-
tients. First in 2003 and again in 2011, the American Council
for Graduate Medical Education implemented new regula-
tions limiting the number of hours that HS can work in the
hospital [6,7]. These changes in the setting of increasing
demand for oncological services [8,9] has led to adaptation of
new care models using alternative care providers such as
APPs [9-12]. Speciﬁcally in the care of ASCT patients, a recent
study demonstrated that APPs were a part of the inpatient
team in 77% of the surveyed institutions, whereas only 24% of
these institutions used HS [4]. Despite this widespread usage
of APPs, little data evaluate the effects of transitioning from
HS to APPs in the setting of ASCT.
The role of APPs in the inpatient care of patients has been
validated in other settings, including general medicinewards
[13,14], the intensive care unit (ICU) [15], trauma service [16],
and most recently inpatient oncology units [17]. These
studies have all found similar overall survival irrespective of
the type of inpatient provider with potential clinical beneﬁts
associated with the implementation of APPs, such as
decreased length of stay (LOS). In contrast to these previous
studies, ASCT patients represent a unique, highly complex
population that is admitted for a speciﬁc procedure with
signiﬁcant morbidity and mortality risk [2,3]. In this study
we compare patient outcomes on a newly developed APP
service compared with a traditional HS service in an inpa-
tient ASCT population.
METHODS
Study Design
A retrospective chart reviewof ASCT patients admitted to the Hospital of
the University of Pennsylvania was performed.
Study Site and Patient Population
We evaluated all patients admitted to Hospital of the University of
Pennsylvania for ASCT from May 2011 to October 2013. Before July 2012 all
ASCT patients were admitted to an HS service. Starting July 2012 all ASCTFigure 1. Consorpatients were to be admitted to a newly developed APP service. Patients
admitted from June 2012 to September 2012 were excluded from analysis
due to transition and crossover that occurred during the initial months of
the new service (Figure 1). This study was reviewed and approved by the
institutional review board at the University of Pennsylvania.
Service Models
HS service
ASCT patients before July 2012 were admitted to an HS service. This
service had a mix of transplant and nontransplant patients with hemato-
logical malignancies. Daytime stafﬁng for the team included 1 attending, a
board-certiﬁed specialist focused on hematological malignancies; 1 ﬁrst-
year medical oncology fellow; 1 medical resident (second- or third-year
resident in an internal medicine training program), and 2 interns (ﬁrst-
year resident in an internal medicine training program). Nighttime coverage
was provided by 1 medical resident and 1 intern. Attending physicians and
HS rotated on 14-day cycles. Both the oncology fellow and the attending
were available overnight for emergent patient issues. Because ASCT is
a planned procedure, all patients were scheduled daytime weekday
admissions.
APP service
Starting July 2012 ASCT patients were admitted to a newly developed
APP service. The service was staffed with 1 attending, drawn from the same
faculty group as those in the HS service, most with a clinical focus in ASCT.
Between 7 a.m. and 7 p.m., Monday through Friday, coverage was provided
by 2 APPs. One APP rotated onto the ASCT service every 3 months from a
larger pool of oncology-speciﬁc APPs. The other APP was assigned exclu-
sively to the ASCT service without rotating off to provide increased conti-
nuity of care. As on the HS service, attending physicians rotated on 14-day
cycles and were available overnight for emergent issues. Nighttime and
weekend coverage was provided by moonlighters who covered multiple
oncology services. All moonlighters were employees of the University of
Pennsylvania health system and consisted of licensed residents and fellows
and occasionally oncology-speciﬁc APPs.
Data Sources and Data Elements
All data were abstracted from our inpatient and outpatient electronic
medical records. Demographic data collected included age, sex, indication
for transplantation, and type of graft donor: sibling, unrelated donor (10/10
or 9/10 match), or cord blood. Graft source was separated into peripheral
blood, bone marrow, or cord. The type of conditioning regimen was iden-
tiﬁed as eithermyeloablative or reduced intensity. The pretransplant disease
status for patients with acute myeloid leukemia (AML) and acute lymphoidt diagram.
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Laboratory values measured includedWBC count, hemoglobin (Hb), platelet
count, and serum creatinine. A hematopoietic cell transplantationespeciﬁc
comorbidity index (HCT-CI) score was calculated for all patients [18], and an
Eastern Cooperative Oncology Group performance status (ECOG PS) [19] was
obtained via chart review.
Outcomes
Primary outcomes were overall and relapse-free survival rates at 100
days post-transplant. Secondary outcomes included LOS, 14- and 30-day
readmission rates, in-hospital death rate, rates of ICU transfers, and infec-
tious complications such as pneumonia (PNA), urinary tract infections,
bacteremia, and Clostridium difﬁcile colitis. Episodes of PNA were measured
by radiological evidence of infection in conjunction with chart review
documentation of treatment. Microbiology data were used to assess for
infectious complications. The ordering behavior of inpatient providers was
measured by recording the number of blood cultures, urine cultures, and
radiological ﬁlms (chest x-rays, computed tomographies, and/or magnetic
resonance images) ordered per patient by each service during the entirety of
the hospitalization. Finally, we evaluated differences in hospital charges
accrued during admission. Hospital charges included laboratory and radio-
logical testing, nursing care, and the transplant itself. We did not take into
account professional or physician billing, which is allocated separately.
Analysis
Primary and secondary analyses
In our primary analysis we compared patient, provider, and cost
outcomes on both HS and APP services before and after the intervention
date of July 2012. During our data collection, we identiﬁed a smaller subset
(n¼ 27) of ASCT patients whowere admitted to the HS service from October
2012 to October 2013. These patients were assigned to the HS service due to
capacity limitations on the APP service. We performed a secondary sensi-
tivity analysis comparing this subset of patients with patients synchro-
nously admitted to the APP service to control for potential calendar time
differences (Figure 2).
Statistical plan
Descriptive statistics were used to compare baseline characteristics
between the 2 study populations. Categorical outcomes were compared
between the HS and APP services using Fisher’s exact test and chi-square
tests. Continuous outcomes were compared using t-tests. We also used
multivariable linear and logistic regression models adjusted for graft source
and HCT-CI score to obtain mean effects and odds ratios, respectively, with
corresponding conﬁdence intervals. All tests were 2-sided, and a P< .05 was
considered statistically signiﬁcant. Analyses were performed using STATA
version 13.0 software (StataCorp LP, College Station, TX, USA).
RESULTS
Primary Analysis (Pre/Post July 2012)
Study population
Patient characteristics for both the primary and second-
ary analyses are listed in Table 1. In the primary analysis, we
evaluated 86 patients on the HS service and 81 patients on
the APP service. There was no difference in the mean age or
sex of the patients on the 2 services, and the leading indi-
cation for ASCT was AML. Among patients with acute leu-
kemia there was no difference in the pretransplant diseaseFigure 2. Study design and primary and secondary analyses. Primary analysis compare
date. Secondary analysis compared HS service (n ¼ 27) to APP service (N ¼ 81) duristatus. Most donors in both groups were unrelated followed
by sibling donors. Unrelated donors were further subdivided
into 10/10 versus 9/10 donors, with no differences (P ¼ .62).
The graft source differed between groups, with more
patients on the HS service (28% versus 10%, P < .01) receiving
bone marrow grafts compared with peripheral blood stem
cells. Laboratory testing on the day of admission revealed
similar results except for Hb, which was signiﬁcantly higher
on the APP service (11.2 g/dL versus 10.5 g/dL, P ¼ .02). There
was no difference in the HCT-CI score among patients
admitted for transplant, but there was a statistically signiﬁ-
cant difference in performance status, with more patients
having a higher ECOG PS on the APP service (Table 1).
Outcomes
Results of our comparative outcomes analysis are shown
in Table 2. Our primary outcomes, the 100-day survival rate
(90% versus 90%, P ¼ .90) and relapse-free survival rate (78%
versus 67%, P¼ .14), were similar in both groups. Mean length
of stay was 29.4 days on the APP service versus 32.1 days on
the HS service (P ¼ .12). There was no difference in read-
mission rates at 14 or 30 days postdischarge (Table 2). There
was a nonestatistically signiﬁcant 6% decrease in deaths
during the hospitalization favoring the APP service (P ¼ .13)
and a 10% decrease in ICU transfers on the APP service
(P ¼ .06). There were less cases of documented PNA on the
APP service (15% versus 28%, P ¼ .04), but other infectious
complications were comparable. With regards to provider
ordering behavior, there were more blood culture orders per
patient (6.7 versus 4.2, P ¼ .03) and a trend toward more
radiological ﬁlm orders per patient (7.8 versus 5.2, P¼ .05) on
the HS service. Mean hospital charges were not different
between the 2 groups (P ¼ .66). Regression analyses adjusted
for graft source and HCT-CI score were performed on the
primary outcomes and other outcomes that reached near
signiﬁcance. These results were not different from unad-
justed analyses (Table 3).Secondary Analysis (October 2012 to October 2013)
Study population
In this secondary sensitivity analysis, we compared the
81 patients admitted to the APP service to the subset of 27
patients admitted to the HS service during the identical time
period from October 2012 to October 2013. In this analysis,
there were no differences in age, sex, underlying disease,
donor type, graft source, disease status, or conditioning
intensity (Table 1). Admission characteristics were similar,
except, as in the primary analysis, there was a statistically
signiﬁcant higher mean Hb on the APP service at admissiond HS service (N ¼ 86) to APP service (N ¼ 81) before and after the intervention
ng concurrent time periods after the intervention date.
Table 1
Patient Characteristics
Variable APP Service
(N ¼ 81)
10/12-10/13
Pre-7/12 HS Service
(N ¼ 86) 5/11-5/12
Two-Sided
P Primary
Analysis*
Concurrent HS Service
(n ¼ 27) 10/12-10/13
Two-Sided
P Secondary
Analysisy
Mean age,z yr 56.8 (11.6) 54.6 (12.6) .24 52.6 (11.2) .10
Sex .36 .65
Female 32 (40%) 40 (47%) 12 (44%)
Male 49 (60%) 46 (53%) 15 (56%)
Diagnosis .13 .25
AML 47 (58%) 46 (54%) 13 (48%)
MDS 12 (15%) 17 (20%) 3 (11%)
ALL 3 (4%) 10 (12%) 4 (15%)
Otherx 19 (23%) 13 (15%) 7 (26%)
Disease status AML/ALLk .44 1.0
Active disease 11 (22%) 9 (16%) 3 (18%)
Remission 39 (78%) 47 (84%) 14 (82%)
Donor type .22 .93
Sibling 29 (36%) 31 (36%) 11 (40%)
Unrelated donor 47 (58%) 54 (63%) 15 (56%)
Cord 5 (6%) 1 (1%) 1 (4%)
Unrelated donors (subdivided){ .62 .12
10/10 matched donor 30 (64%) 37 (69%) 13 (87%)
9/10 matched donor 17 (36%) 17 (31%) 2 (13%)
Graft source <.01# .28
BM 8 (10%) 24 (28%) 6 (22%)
PB 68 (84%) 61 (71%) 20 (74%)
Cord 5 (6%) 1 (1%) 1 (4%)
Conditioning .27 .14
Reduced intensity 52 (64%) 48 (56%) 13 (48%)
Myeloablative 29 (36%) 38 (44%) 14 (52%)
Mean admit WBC count,z k/mL 5.7 (3.6) 5.8 (4.7) .91 5.3 (5.4) .66
Mean admit Hb,z g/dL 11.2 (2.2) 10.5 (1.8) .02# 10.1 (2.2) .03#
Mean admit PLT,z k/mL 155 (90) 146 (87) .52 148 (115) .75
Mean admit Cr,z g/dL .83 (.21) .88 (.30) .21 .86 (.22) .52
ECOG PS** .03# .12
0-1 65 (84%) 68 (96%) 17 (100%)
2-3 12 (16%) 3 (4%) 0 (0%)
HCT-CI score .10 .44
0 11 (13%) 9 (11%) 4 (15%)
1-2 41 (51%) 32 (37%) 10 (37%)
3 29 (36%) 45 (52%) 13 (48%)
MDS indicates myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; BM, bone marrow; PB, peripheral blood; PLT, platelets; Cr, creatinine.
* This is the P value for the primary analysis (before/after the intervention date). It compares baseline characteristics of the APP service in the ﬁrst column
(shaded) to HS service in the second column.
y This is the P value for the secondary analysis (patients admitted during the same time period). It compares baseline characteristics of the APP service in the
ﬁrst column (shaded) to the HS service in the fourth column.
z Values in parentheses represented standard deviation for continuous outcomes and percentage involved for categorical outcomes.
x Other diagnoses include myeloproliferative disorders, chronic myeloid leukemia, non-Hodgkin lymphomas, multiple myeloma, and aplastic anemia.
k The pretransplant disease status was assessed only in patients with AML and ALL.
{ Unrelated donors were further subtyped into 10/10 vs. 9/10 match.
# Statistically signiﬁcant P < .05.
** Includes only patients with documented ECOG PS.
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in HCT-CI score or ECOG PS between the 2 groups.
Outcomes
In our secondary analysis, adjusted regression models
were not used to evaluate outcomes because all relevant
confounders were balanced between the 2 comparison
groups. With respect to this sensitivity analysis, LOS was
longer on the HS service (37.2 days versus 29.4 days, P ¼ .01)
than on the APP service. There were no differences in rates of
readmission, in-hospital death, ICU transfers, or infectious
complications among the 2 provider groups (Table 2). In
terms of provider behavior, the HS service ordered more
radiological ﬁlms (8.1 versus 5.2, P ¼ .05) and blood cultures
(9.3 versus 4.2, P < .01) than the APP service. Hospital
charges were signiﬁcantly higher on the HS service than on
the APP service ($597,482 versus $465,501, P ¼ .04). Rates of
100-day survival (89% versus 90%, P ¼ 1.0) and relapse-freesurvival (78% versus 78%, P ¼ 1.0) were the same in both
groups.
DISCUSSION
ASCT is a high-risk, costly procedure that offers the only
chance of cure in some patients with hematological malig-
nancies. Patients admitted for this procedure are generally
hospitalized for 4 to 6 weeks and can have a hospital course
complicated by infection, graft-versus-host disease, or organ
failure [1-3]. Logistically, these patients have a complex
discharge process, with most patients going home with
central venous access and complicated medication regimens.
In this study we evaluated outcomes of patients undergoing
ASCT on a newly developed APP service and found this
alternative model of care resulted in similar survival rates as
those patients receiving care on a traditional HS service. This
is the largest study evaluating patient outcomes by inpatient
provider type in oncology and the ﬁrst to look at outcomes of
Table 2
Patient Outcomes
Variable APP Service (N ¼ 81)
10/12-10/13
Pre-7/12 HS Service
(N ¼ 86) 5/11-5/12
Two-Sided
P Primary
Analysis*
Concurrent HS Service
(n ¼ 27) 10/12-10/13
Two-Sided
P Secondary
Analysisy
Mean LOS,z days 29.4 (9.0) 32.1 (12.9) .12 37.2 (23.3) .01x
14-day readmission 16 (20%) 19 (25%) .54 2 (8%) .23
30-day readmission 25 (32%) 27 (35%) .69 5 (21%) .44
Death during ASCT 3 (4%) 9 (10%) .13 3 (11%) .16
ICU transfers 7 (9%) 16 (19%) .06 4 (15%) .36
PNA 12 (15%) 24 (28%) .04x 7 (26%) .19
UTI 10 (12%) 9 (10%) .70 6 (22%) .21
Clostridium difﬁcile colitis 15 (19%) 21 (24%) .35 5 (19%) 1.0
Bacteremia 14 (17%) 23 (27%) .14 8 (30%) .17
Mean no. of ﬁlms per patientz 5.2 (5.6) 7.8 (10.7) .05 8.1 (8.7) .05x
Mean no. blood culture orders per patientz 4.2 (5.3) 6.7 (8.4) .03x 9.3 (12.3) <.01x
Mean no. urine culture orders per patientz 1.5 (1.5) 1.5 (1.5) .85 2.2 (2.5) .06
Mean hospital charges per patient,z US$ 465,501 (212,452) 449,679 (246,843) .66 597,482 (439,931) .04x
Alive at day 100 73 (90%) 77 (90%) .90 24 (89%) 1.0
Alive and relapse free at day 100 63 (78%) 58 (67%) .14 21 (78%) 1.0
UTI indicates urinary tract infection.
* This is the P value for the primary analysis (before/after the intervention date). It compares outcomes of the APP service in the ﬁrst column (shaded) to HS
service in the second column.
y This is the P value for the secondary analysis (patients admitted during the same time period). It compares outcomes of the APP service in the ﬁrst column
(shaded) to the HS service in the fourth column.
z Values in parentheses represented standard deviation for continuous outcomes and percentage involved for categorical outcomes.
x Statistically signiﬁcant P < .05.
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ASCT patients have a unique complexity yet are uniform in
the timing and indication for admission.
In our primary analysis, baseline characteristics revealed
that these 2 services had comparable patient populations
other than graft source. No major differences were seen in
patient demographics, indication for transplant, or type of
transplant performed. Although the ECOG PS suggested
a higher acuity on the APP service, this information was
incomplete because not all patients had documented
scores. With regards to outcomes, we found no difference in
100-day survival or 100-day relapse-free survival rates, a
standard time point for the assessment of ASCT patients.
This was accomplished by the APP service with no increase
in deaths during ASCT or change in readmission rates.
Additionally, there were signiﬁcantly less episodes of PNA
on the APP service as well as nonestatistically signiﬁcant
decreases in ICU transfers and LOS on the APP service. There
were less blood cultures and a trend toward less radiological
ﬁlms ordered on APP service, suggesting that continuity of
care in the APP model may lead to decreased utilization.
To account for imbalances in graft source and HCT-CI scoreTable 3
Primary Analysis Adjusted Regression Models*
Binary Outcomes Adjusted
Odds Ratio
for HS
P 95% Conﬁdence
Interval
Dead at day 100 1.12 .84 .37-3.35
Dead or relapsed
at day 100
2.03 .06 .96-4.25
PNA 2.39 .04y 1.05-5.45
ICU transfers 1.72 .09 .89-6.58
Continuous Outcomes Adjusted
Coefﬁcient
for HS
P 95% Conﬁdence
Interval
Blood culture orders 2.26 .05y .04-4.49
Radiological ﬁlm orders 2.38 .09 .41 to 5.15
* Multivariable logistic and linear regression models for the primary
analysis were performed adjusting for graft source and HCT-CI score.
y Statistically signiﬁcant P < .05.seen in our baseline characteristics, multivariable regression
analyses were performed. Results of these analyses were
consistent with our comparative analysis demonstrating
increase odds of PNA on the HS service and increase in blood
culture orders on the HS service with no difference in
100-day survival outcomes.
It can be hypothesized that an APP model, through
development of provider expertise, creates an opportunity
for the delivery of high-level, consistent care in this very
unique patient population. Additionally, given the proto-
colized nature of ASCT, APPs have an inherent advantage of
familiarity with the transplant process due to ongoing
exposure. Finally, the similar 100-day patient outcomes may
reﬂect the role of the attending physician, which remained
constant in both service models. In our study, the newly
developed APP service provided comparable quality care as
indicated by outcomes, LOS, and similar rates of complica-
tions as patients treated by HS.
A unique feature of our study was our ability to compare
outcomes before and after the intervention date in our pri-
mary analysis and concurrently in our secondary analysis.
This latter analysis allowed us to compare a subset of ASCT
patients admitted to the HS service with patients admitted to
the APP service over the same time period, eliminating the
effect of secular trends. This was demonstrated by our
baseline patient characteristics that revealed a more equiv-
alent patient population than in our primary analysis. In this
secondary analysis, there was no difference in readmission
rates, ICU transfers, or infectious complications. Interest-
ingly, we found an increased LOS that was associated with
increased test ordering and, consequently, an increase in
mean hospital charges on the HS service. These outcomes
support trends observed in our primary cohort. One expla-
nation for the ﬁndings in this analysis is that limiting HS
exposure to allogeneic transplant decreases familiarity with
this patient population, resulting in longer hospitalizations
and increased ordering behavior. Alternative explanations
are that these patients differed in disease severity in ways
that were nonmeasureable or that there was selection bias in
patient triage.
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ports the role of APPs in clinical settings that have tradi-
tionally been ﬁlled by residents [13-17]. In a retrospective
review of 2 ICUs staffed by APPs and HS, respectively,
patients had similar mortality, LOS, and rates of discharge to
skilled care facilities [15]. A previously published study
conducted at the University of Pennsylvania evaluated the
care of trauma patients admitted to an HS service compared
with an APP service. Results of this analysis found no dif-
ference in ICU transfers or readmission rates with a trend
toward decreased LOS in the APP group [16]. Within the
practice of oncology, a study evaluating outcomes of patients
admitted for reinduction chemotherapy for AML by provider
type (HS versus APP) found no difference in mortality or ICU
transfers but did describe decreased LOS and lower read-
mission rates on the APP service [17].
Although we demonstrate similar 100-day outcomes, and
possibly even beneﬁts of implementation of a transplant-
speciﬁc APP service, we must consider both the ﬁnancial
costs and potential educational loss to HS before widespread
implementation of these novel care models. Although a
complete cost analysis is beyond the scope of this study, it is
of interest to consider that salaries of full-time APPs are
double that of trainees, and in our practice model, there is
the added costs of moonlighters for overnight coverage [20].
Furthermore, removal of HS from the care of ASCT patients
may have a negative impact on the physician workforce
prepared to treat these patients. Studies have predicted sig-
niﬁcant shortages in oncology and in bone marrow trans-
plantation in particular, leading to calls for increased trainee
engagement in transplantation as a means of improving
recruitment into the ﬁeld [8,21]. There are also potential
educational losses for residents and fellows in training as
their roles are transitioned to APPs, although some studies
have suggested that skilled APPs may add to the educational
experience of HS [22,23]. Our study suggests that limiting the
exposure that HS have with ASCT may prolong the LOS and
lead to increased hospital charges. Future research will need
to be performed to determine if ASCT should remain a part of
HS training.
There are several limitations of this study design. A
retrospective cohort study limits data collection to that
available in the clinical record. As a single-center study, there
are restrictions to generalizability, but because most ASCTs
are performed at academic centers [24], our ﬁndings can be
applicable to many transplant centers who have or are
considering implementation of APP services. Additionally,
our primary analysis has inherent limitations due to un-
measurable changes that may have occurred with institu-
tional practices over time. However, our primary ﬁndings are
found to be robust when evaluated in a secondary analysis
comparing concurrent groups of patients exposed to the HS
and APP services, respectively. Our study is also restricted
by sample size with limited power to detect a difference
in 100-day survival rates. Notably, for our primary analysis
100-day survival outcome, post-hoc power calculations
demonstrate that wewould need 446 subjects in each arm to
be 80% sure the upper limit of a 1-sided 95% conﬁdence
interval will exclude a difference in favor of the HS group of
more than 5%. This sample size was not feasible given our
study population, and we acknowledge the lack of an
observed difference in 100-day survival rates may be a
consequence of limited power. Finally, we did not separate
the effect of moonlighters in this study but rather included
them as part of the APP service model.In conclusion, in the care of ASCT patients, a specialized
service using APPs provided similar 100-day overall survival
and relapse-free survival rates with potential beneﬁts
including decreased test ordering. In the setting of work-
hour regulations limiting HS resources, this study suggests
that a service incorporating APPs is an acceptable model in
the care of complex ASCT patients. As we use these models in
the future, it will be important to consider the impact on
patient outcomes, physician training and education, and the
value of care provided.
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